Arimidex®: A potent and selective fourth-generation aromatase inhibitor

@article{Plourde1994ArimidexAP,
  title={Arimidex®: A potent and selective fourth-generation aromatase inhibitor},
  author={Paul V. Plourde and Martin C. Dyroff and Michael Alan Dukes},
  journal={Breast Cancer Research and Treatment},
  year={1994},
  volume={30},
  pages={103-111}
}
Arimidex® is a potent and selective aromatase inhibitor undergoing evaluation as a treatment for postmenopausal women with advanced breast cancer. Studies to determine the pharmacology of Arimidex were conducted in both animals and humans. In animals, Arimidex was selective for the aromatase enzyme, elicited maximal activity at about 0.1 mg/kg, did not interfere with steroid hormones produced by the adrenal glands, and, at a dose of 1 mg/kg, had no detectable pharmacologic activity other than… CONTINUE READING
59 Citations
8 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 59 extracted citations

References

Publications referenced by this paper.
Showing 1-8 of 8 references

Falkson HC: A study of Fadrazole, a new aromatase inhibitor, in postmenopausal women with advanced metastatic breast cancer

  • JI Raats, G Falkson
  • J Clin Oncol 10:111-116,
  • 1992
1 Excerpt

Misbin RI: Aminoglutethimide: review of pharmacology and clinical use

  • RJ Santen
  • Pharmacotherapy 11:95-120,
  • 1981
1 Excerpt

Similar Papers

Loading similar papers…